Previous 10 |
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update $207.6 million cash balance expected to provide funding for operations into 2023 Continue to advance potentially registration enabling Phase 2 studies for mecbotamab vedotin (BA3011) and ozu...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The big event next week could be the two-day FOMC meeting that will conclude with a policy statement and Jerome Powell p...
BioAtla (BCAB): Q1 net loss was $18.7M vs. a loss of $1.6M in last year's quarter.Cash and cash equivalents as of March 31, 2021 were $221.2 million.Press Release For further details see: BioAtla reports Q1 results
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update - Initiated potentially registration-enabling Phase 2 studies for our CAB-AXL-ADC in refractory sarcoma patients and NSCLC patients refractory to EGFR or PD-1/L1 inhibitors - Initiated potent...
BioAtla (BCAB): FY net loss of $35.85MRevenue of $0.43M (-91.7% Y/Y) misses by $1.18M.Shares -0.67%.Press Release For further details see: BioAtla misses on revenue
BioAtla is developing selectively-targeting antibodies based on very interesting science. However, it is a new IPO, and current prices and cash reserves are not conducive to investment. This is one to add to your watchlist. For further details see: BioAtla: Intriguing Sc...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety w...